Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

AUTOIMMUNE DISEASES STATISTICAL & CLINICAL COORDINATING CENTER (AD-SCCC)

Open
75N93026R00009Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH) is seeking to extend the contract for the Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC). This project provides essential support for the design, development, execution, and analysis of clinical research focused on autoimmune diseases, mucosal immunology, and primary immune deficiencies. The scope of work includes supporting the Autoimmunity Centers of Excellence and Immune Tolerance Network (ACE) and investigator-initiated clinical trials (IICT). Key responsibilities encompass statistical design and analysis, protocol development, data management, clinical safety and pharmacovigilance support, and the management of biological specimen repositories and collaboration portals. The NIAID intends to negotiate a sole source modification with Rho Federal Systems Division, Inc. under FAR Part 6.302-1 and HHSAR Part 306.302-1 to avoid significant disruptions to critical services and ensure participant safety and data integrity. The proposed 18-month extension is structured as two discrete option periods: a 12-month period from February 1, 2027, through January 31, 2028, and a 6-month period through July 31, 2028. This extension maintains the existing term type/level of effort contract structure and scope to ensure continuity of operations while the agency completes a separate competition process.

General Info

NIAID is extending a sole source contract with Rho Federal Systems Division.

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Durham, NC, 27713, USA

Set-Aside

NONE

Documents

1
PDF, Low prioritypresolicitation
Low

Read the document

Due in 15 days

Every page of every file, in your free workspace.

Read the document

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

View Full Breakdown
Due in 15 days

Everything you need to bid on this one

Open the full contract in your free workspace.

  • 1 solicitation documentRead every page
  • AI contract breakdown13 sections, Uniform Contract Format
  • Buyer contactEmail and phone
Open the full contract

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

PhasePresolicitation
Posted

Presolicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
Contacts2 people available
OfficeBETHESDA, MD, 20892, USA

Full Description

Show more

Anticipated Period of Performance


The anticipated period of performance is February 1, 2027 through January 31, 2028, with an option to extend services for an additional 6 month period, through July 31, 2028.


Anticipated award date:  February 1, 2027


The NAICS Code is 541715.


Introduction


The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases.  The NIAID, Division of Allergy, Immunology, and Transplantation (DAIT) has a requirement to support a broad range of services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. The major clinical research programs to be supported by this solicitation include, Autoimmunity Centers of Excellence and Immune Tolerance Network (ACE), as well as investigator initiated clinical trials (IICT), and other clinical trials or study activities supported by NIAID herein collectively referred to as NIAID supported research.


Description


Topic Title: Autoimmune Diseases Statistical & Clinical Coordinating Center (ADSCCC)


The Division of Allergy, Immunology, and Transplantation (DAIT), National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), project is for work related to the contract below:


“Autoimmune Diseases Statistical & Clinical Coordinating Center (AD-SCCC)”, RHO Federal Systems Division, Inc. (Contract 75N93022C00003)


This contract was awarded on a competitive basis for a five-year period from February 1, 2022 through January 31, 2027. A term type/level of effort contract was awarded for the delivery of 56,170 direct labor hours per year for Years 1-5. The total value of the contract is $49,268,667 and includes options for extension of the term for a total performance period of 5 years and options for increases in the level of effort, with the purpose of establishing an Autoimmune Diseases Statistical & Clinical Coordinating Center (AD- SCCC) that will provide a broad range of support critical for the design, development, execution, and analysis of clinical research sponsored by NIAID in autoimmune diseases and diseases related to mucosal immunology and primary immune deficiencies. The scope of clinical research to be supported by the AD- SCCC includes: (i) clinical trials at all phases to evaluate the safety and efficacy of investigational products and innovative approaches for disease treatment and prevention; (ii) studies of underlying mechanisms as integral components of clinical trials; (iii) clinical studies (e.g., genetic studies, microbiome studies, surveys of current therapies, etc.); and (iv) surrogate/biomarker studies. The scope of statistical and clinical support functions to be performed by the AD-SCCC includes statistical design and analysis; protocol development; study initiation and management; clinical safety and pharmacovigilance support; safety oversight; management of clinical study collaboration portals; manuscript preparation and management of sample repositories.


The NIAID, NIH, conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.  The causes, pathogenesis, diagnosis, treatment, and prevention of autoimmune diseases are major areas of emphasis for NIAID’s Division of Allergy, Immunology, and Transplantation (DAIT).  DAIT pursues research on autoimmune diseases by supporting investigator-initiated research projects, cooperative clinical studies, national networks of research centers, and demonstration and education research projects.  A critical component of the Division’s mission focuses on clinical research to develop new and/or improved strategies to treat or prevent autoimmune diseases through rigorous evaluations of the safety and efficacy of investigational products and therapeutic interventions, studies to elucidate underlying mechanisms of disease, studies to develop and evaluate surrogate/biomarkers of disease stage, severity and progression, and clinical studies of disease natural history.


The purpose of this acquisition is to extend the period of performance of the current contract (through July 31, 2028), beginning February 1, 2027, thereby maintaining the same direct labor hours to maintain ongoing clinical trial operations while DAIT completes the competition under the Clinical Data, Safety, and Coordinating Centers (CDSCC) NOFO. The extension retains the existing scope and contract type. The required research and development clinical trial activities are severable in nature, the 18-month extension will be structured as two discrete option periods.


Specifically, the Contractor will be responsible for the following:


A.        Statistical Design


  1. Provide expertise, advice and assistance pin the development of statistical design plans for the development of concept and full study proposals for NIAID supported clinical research;
  2. Provide assistance in the preparation of concept and full proposals and study-specific protocols;
  3. Provide assistance in the preparation of concept and full proposals and protocols for mechanistic studies;
  4. Provide support for preclinical safety study evaluation by providing statistical expertise for, and participate in, evaluating the accuracy and validity of data from preclinical safety studies in support of clinical trials if applicable;
  5. Provide assistance for clinical trials and mechanistic studies post-study initiation.

B.         Statistical Analysis


  1. Development and preparation of the Statistical Analysis Plan (SAP) for each clinical trial in conjunction with the Study Management Teams (SMTs);
  2. Preparation of interim and final analyses;
  3. Preparation of summary data reports;
  4. Development and preparation of results for posting as required by ClinicalTrials.gov;
  5. Review of the accuracy and completeness of statistical data and data analyses for all abstracts, manuscripts, and presentations reporting on the clinical studies conducted by the relevant NIAID-sponsored networks and investigators prior to presentation or submission for publication.
  6. Collaboration with NIAID-supported research, including the NIAID Clinical Data and Safety Management Center (CDSMC);

C.        Protocol Development and Study Initiation


  1. Provide expert advice and assistance to SMTs in the development of protocols for clinical trials and mechanistic studies;
  2. Provide expert advice, assistance and coordination in the preparation, writing, review and approval of protocol-related documents and materials in collaboration with NIAID, SMTs, and the CDSMC and other NIAID supported research.

D.        Data Management and Reporting


E.         Clinical Safety and Pharmacovigilance Center Support


F.         Safety Oversight Structure Support


G.        Clinical Study Internet-Based Collaboration Portals


H.        Training


I.          Repository of Biological Specimens


J.         Other Technical and Administrative Support


K.        Scientific and Technical Personnel


L.         Facilities, Equipment and Other Resources


M.        Quality Assurance/Quality Control


N.        Overall Project Management


O.        Initial and Final Transitions


The NIAID intends to negotiate, under the authority of RFO - FAR Part 6.302-1 and HHSAR Part 306.302-1, on a sole source basis with Rho, to modify the existing contract to extend the current contract by a total of 18-months [Term Option 5 (12-months, February 1, 2027 through January 31, 2028), and Term Option 6 (6-months, February 1, 2028 through July 31, 2028)]. Due to the complex nature of DAIT clinical trial operations and the need for a contractor to perform the required AD-SCCC services during the interim period, the requirement is to maintain support for the existing portfolio without an interruption in protocol operations, statistical support, data coordination, or safety oversight beginning February 1, 2027. Rho’s demonstrated personnel qualifications, staffing, relevant experience, and current protocol-specific knowledge support its ability to meet that requirement.


Attempting to bring in a new contractor would result in a significant disruption to critical services and could jeopardize participant safety and data integrity. Using the current contractor for the extension of services allows for continuity of operations in this highly regulated environment and helps to ensure we are able to maintain during this interim period the services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases.


This notice of intent is not a request for competitive proposals.  However, responsible sources may express their interest by submitting a capability statement.  All capability statements received within fifteen days from the date of the publication of this notice will be considered by the Government.  A determination by the Government not to compete this proposed contract action based upon responses to this notice is solely within the discretion of the Government.  Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. 


This proposed acquisition was previously published under a Research and Development Sources Sought Notice that was posted on the System for Award Management (SAM.gov) website on February 20, 2026 as notice number HHS–NIH–NIAID–RDSS–26–75N93026R00009.

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
SBIR / STTR
Ground-Based Affordable Mass (G-BAM)
Solicitation # ARM26BX04-DV010
The Ground-Based Affordable Mass (G-BAM) solicitation, issued by the U.S. Army under the U.S. Department of Defense, is a total small business set-aside opportunity utilizing a direct-to-Phase II SBIR structure. The program is designed as a three-phased effort, where Phase I typically lasts six to twelve months and Phase II generally spans 24 months. Proposals are submitted via the DSIP portal and must be organized into seven specific volumes, including technical, cost, and commercialization reports. Technical proposals must adhere to strict formatting guidelines, including a single PDF format, one-inch margins, and a minimum 10-point font, with a risk of rejection if page limits are exceeded. Award selections are based on the overall technical value and cost, with a primary focus on technical capability, innovation, and the qualifications of key personnel. Evaluation factors are prioritized by the soundness of the technical approach, the ability of the team to perform R&D and commercialize results, and the overall commercial potential for government or private sector application. To be eligible, proposing entities must be registered in the System for Award Management (SAM) and the SBA Company Registry. Additionally, contractors must comply with stringent security and legal requirements, including the Cybersecurity Maturity Model Certification (CMMC) program, Foreign Risk Evaluation (FRE), and the disclosure of any organizational conflicts of interest.
U.S. Army

POSTED

about 10 hours ago

DEADLINE

in 14 days
View Details
NAICS: 541715
New
Federal
UNITED STATES ARMY RESEARCH INSTITUTE FOR THE BEHAVIORAL AND SOCIAL SCIENCES (ARI) BROAD AGENCY ANNOUNCEMENT FOR BASIC, APPLIED, AND ADVANCED SCIENTIFIC RESEARCH
Solicitation # W911NF-23-S-0010
Broad Agency Announcement W911NF-23-S-0010 is a multi-year solicitation issued by the United States Army Research Institute for the Behavioral and Social Sciences (ARI) to acquire basic, applied, and advanced scientific research. Valid from May 1, 2023, to April 30, 2028, the BAA focuses on enhancing Army readiness and performance through the behavioral and social sciences. Key research areas include holistic personnel assessment, job classification and assignment, leadership development for organizational and strategic leaders, team composition and effectiveness in future operational environments, and the assessment of technological fluency. The acquisition process typically follows a three-step sequence: initial contact with an ARI Technical Point of Contact, submission of a white paper (limited to six pages), and a subsequent full proposal if encouraged. Proposals are evaluated based on scientific and technical merit, potential contribution to the ARI mission, qualifications of key personnel, and cost, with technical merit weighted most heavily. Award instruments may include contracts or grants, with specific project budgets ranging from approximately 320,000 dollars for creative performance research to 1.35 million dollars for career progression studies. Administrative requirements include registration in the System for Award Management and the provision of CAGE codes and Taxpayer Identification Numbers. Proposals must adhere to strict formatting guidelines, including a 23-page limit for core technical sections. Special provisions are in place regarding Organizational Conflicts of Interest, particularly for entities with existing Intergovernmental Personnel Act agreements, and strict prohibitions against including classified information in white papers.
W6QK Acc-Apg Durham

POSTED

about 11 hours ago

DEADLINE

in over 1 year
View Details
NAICS: 541715
New
Federal
Notice of Intent (NOI) to Sole Source proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs)
Solicitation # HT9426-27-NOI-049825
The Defense Health Agency, on behalf of the Walter Reed Army Institute of Research, has issued a Notice of Intent to sole source the procurement of the proprietary prodrug MP201 to the Integrative Systems Biology (ISB) Branch. The primary objective is to support the testing of Acute Stress Reactions (ASRs). The scope of work requires the contractor to supply two freshly made batches of MP201 synthesized for oral administration in mice, with target dosages ranging approximately from 8 to 80 mg/kg body weight. In addition to the physical product, the contractor must provide quality control documentation, dosage background information, and technical support to assist the ISB research team in preparing related reports and manuscripts. This action is identified by solicitation number HT9426-27-NOI-049825 and is categorized under NAICS code 541715. As this is a Notice of Intent and not a request for competitive proposals, no formal solicitation document or pricing data is currently available. Interested parties must submit capability statements in writing via PDF, MS Word, or Excel to Herbert Keen or Lance Nowell by 2:00 p.m. Eastern Time on December 31, 2026. All submissions must be unclassified, as the agency has explicitly stated that classified material should not be submitted.
Defense Health Agency

POSTED

about 11 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541715
New
Federal
Office of Hazardous Materials Safety Research Initiative – FY2026 BROAD AGENCY ANNOUNCEMENT (BAA)
Solicitation # PHMSA-26HM-BAA
The U.S. Department of Transportation's Pipeline and Hazardous Materials Safety Administration (PHMSA) is soliciting research proposals under Broad Agency Announcement PHMSA-26HM-BAA to advance safety and prevent incidents during the transportation of hazardous materials. The initiative focuses on five core topic areas: Efficient Safety Standards (26HM-ESS), Safe Energy Storage Technologies (26HM-SST), Innovative Packaging (26HM-IPG), Risk Reduction for Emergency Response (26HM-RER), and Hazardous Materials Rail Transportation Safety (26HM-RTS). Eligible applicants include U.S.-based industry, accredited universities, non-profits, and permitted federally affiliated research centers, while foreign entities may only participate as subcontractors. The selection process consists of two phases, beginning with a Phase I white paper due November 18, 2026, followed by invited Phase II full proposals. Awards will be issued as Firm-Fixed-Price or Cost-Reimbursement procurement contracts with a ceiling of $2,000,000 per independent submission and a performance period of up to 36 months. Evaluation for Phase I is based on technical merit and feasibility (35%), relevance to program mission (35%), experience and qualifications (20%), and submission quality (10%). Phase II adds cost realism as a weighted factor. Awarded contractors must provide regular progress reports, a data management plan, and a plain-language project one-pager.
693JK3 Acquisition Services Division

POSTED

about 11 hours ago

DEADLINE

in 1 day
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Niaid

Same awarding agency

NAICS: 541715
Federal
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
Solicitation # HHS-NIH-NIAID-BAA2026-1
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals under Broad Agency Announcement HHS-NIH-NIAID-BAA2026-1 to advance medical interventions for infectious diseases. The initiative focuses on three primary research areas: the development of needle-free vaccine candidates through early phase clinical trials for viral pathogens; the creation of safe and effective therapeutic products for serious infectious diseases that are currently untreatable or drug-resistant; and the innovation of in vitro diagnostic technology platforms capable of rapid, point-of-care detection of priority viral families. For Fiscal Year 2027, NIAID estimates a total award amount of up to 16 million dollars for the non-severable base awards, with the potential for cost-reimbursement contracts lasting up to five years. Proposals must be submitted electronically via the eCPS portal by December 8, 2026, at 3:00 PM Eastern Time. Technical proposals are limited to 75 pages and will be evaluated by a peer review group based on scientific and technical merit, which is the paramount consideration for award. While cost is a factor, it is significantly less important than technical acceptability. Awardees will be required to adhere to Good Manufacturing Practice (GMP) for drug products and comply with HHS Section 508 accessibility standards. Key personnel must be named in the award, and a mandatory kick-off meeting is required within 60 days of the effective award date.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

12 days ago

DEADLINE

in 22 days
View Details

Earlier notices in this NAICS code

Posted before this notice, open and closed

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS